New Prostate Cancer Biomarkers Can Improve Precision Therapy
Improvements are on the horizon in the treatment of prostate cancer that could improve future therapy.
Regardless of treatment modality, men with Gleason 10 prostate cancer have high 5-year overall survival rates, new study finds.
Early study results are encouraging, but high-quality data that validate PET/CT against a reliable reference standard are lacking.
MRI with targeted prostate biopsy plus systematic biopsy fails to improve detection of upgrading in men on active surveillance for prostate cancer vs systematic biopsy alone.